Case Report: Treatment of Diffuse-Type Tenosynovial Giant Cell Tumor with Vimseltinib
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Case Report: Treatment of Diffuse-Type Tenosynovial Giant Cell Tumor with Vimseltinib Background Tenosynovial Giant Cell Tumor (TSGCT) is a rare, benign proliferative disorder involving the synovial lining of joints, bursae, and tendon sheaths. The diffuse subtype (D-TSGCT) is particularly uncommon, with an estimated incidence of approximately 5 cases per million person-years. It is locally aggressive and can be challenging to manage, particularly when surgical resection is incomplete. Case Presentation A middle-aged male with no prior history of trauma presented to his primary care physician with progressive right knee pain, stiffness, and swelling over the course of one year. He was initially diagnosed with a meniscal injury and treated conservatively with nonsteroidal anti-inflammatory drugs (NSAIDs) before being referred to an orthopedic specialist. Magnetic resonance imaging (MRI) revealed hemosiderin deposition along the synovium, raising suspicion for diffuse-type TSGCT. Despite surgical intervention, the patient reported only minimal symptomatic improvement. He was subsequently referred to a hematologist-oncologist and initiated on Vimseltinib, a selective CSF1R inhibitor. Within two weeks of therapy, the patient experienced marked improvement in knee pain, stiffness, and swelling. Discussion TSGCTs are driven by overexpression of colony-stimulating factor 1 (CSF1) due to chromosomal translocations, leading to recruitment of CSF1 receptor (CSF1R)-expressing cells and subsequent tumor growth. Complete surgical excision is often difficult, especially in diffuse cases, and recurrence is common following incomplete resection. This case illustrates the efficacy of Vimseltinib, an oral, selective CSF1R inhibitor recently approved by the FDA for the treatment of TSGCT. The patient demonstrated significant clinical improvement shortly after initiation of therapy, highlighting the potential of targeted pharmacologic treatment as a viable alternative or adjunct to surgery in managing diffuse-type TSGCT.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.002 |
| Meta-epidemiology (broad) | 0.003 | 0.000 |
| Bibliometrics | 0.004 | 0.010 |
| Science and technology studies | 0.001 | 0.011 |
| Scholarly communication | 0.000 | 0.001 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.005 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it